Pegylated factor VIII
AssigneesBaxter International Inc., Baxter Healthcare S.A.
InventorsJuergen Siekmann, Katalin Varadi, Herbert Gritsch, Peter Turecek
Life of this patent
Estimating the term…
Abstract
The invention is a proteinaceous construct comprising a Factor VIII molecule having at least a portion of the B domain intact, which is conjugated to a water-soluble polymer such as polyethylene glycol having a molecular weight of greater than 10,000 Daltons. The construct has a biological activity of at least 80% of the biological activity of native Factor VIII, and the in vivo half-life of the construct is increased by at least 1.5 fold as compared to the in vivo half-life of native factor FVIII.
Claims9
A proteinaceous molecule comprising, (a) a Factor VIII molecule having the B domain intact;
- and (b) at least four polyethylene glycol molecules bound to said Factor VIII molecule, wherein three polyethylene glycol molecules are bound to said Factor VIII molecule in the A3 domain and at least one polyethylene glycol molecule is bound to said Factor VIII molecule in the B domain;
- said polyethylene glycol molecules having a molecular weight of about 15,000 Daltons to about 150,000 Daltons;
- said proteinaceous molecule having a biological activity of at least 80% of the biological activity of native Factor VIII, wherein the biological activities of the proteinaceous molecule and of native Factor VIII are determined by the ratios of chromogenic activity to Factor VIII antigen value (FVIII:Chr/FVIII:Ag), and wherein the in vivo half-life of said proteinaceous molecule is increased by at least 1.5-fold as compared to the in vivo half-life of native Factor VIII.
Dependencies are inferred from the claim text.